|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008
Decision Resources, Inc., Oct 2008, Pages: 30
Governments in Europe and Japan have long exercised strict control over prices in their national pharmaceutical markets, and they give every indication of tightening their grip on drug manufacturers. Recent evidence nsuggests that U.S. politicians and payers are devoting unprecedented attention to measures to curb spending in the world’s largest pharmaceutical market, a disturbing turn of events for manufacturers of branded drugs.
Get the Answers You Need to Shape Your Strategy
- U.S. employers are altering their formulary designs and increasing their use of utilization management tools. What are the most common formulary designs in 2008? What out-of-pocket payments are employers requiring their employees to make for prescription drugs? Which cost-containment measures are becoming more common in the United States?
- The French government has announced plans for healthcare reforms in its 2009 budget. How will the pricing of generic drugs change? What measures are proposed to expand the scope of the reference pricing system? How will the funding of high-priced drugs in the hospital sector change?
- The implementation of healthcare reforms passed in Germany in 2007 is progressing slowly. Which drug class will be the fi rst subjected to a requirement for a second opinion from a qualifi ed specialist? What is the timetable for implementation of health economic evaluation? What measure is the German government considering to recoup money lost by the statutory health insurance system as a result of the delays in introducing maximum reimbursement sums?
- The U.K. government prematurely terminated the 2005 Pharmaceutical Price Regulation Scheme (PPRS) on August 31, 2008. What plans does the government have for a new system in 2009? What interim measures have been implemented pending the introduction of the new PPRS?
Scope
- Issues affecting the pharmaceutical industry in the United States: changing patterns of health insurance coverage; evolution of drug benefi t designs; Medicare reform; calls for Medicare Part D discounts to match savings available to Medicaid.
- Issues affecting the pharmaceutical industry in Europe: reforms proposed by the French government for 2009; slow progress on implementation of German reforms passed in 2007; market trends in Italy; amendments to the Spanish reference pricing system; reform of the United Kingdom’s
Pharmaceutical Price Regulation Scheme.
- Issues affecting the pharmaceutical industry in Japan: industry proposal for pricing reform; measures to stimulate the generics market; resistance to calls for introduction of reference pricing
Also available
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008
Customers who bought this item also bought
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Pharmaceutical Pricing and Reimbursement in the United States, 2008
Pharmaceutical Pricing and Reimbursement in Italy, 2008
The Pricing and Reimbursement Environment for Neurology Drugs
Pharmaceutical Pricing and Reimbursement in Japan, 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
|
|
|
|
